S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This randomized phase II trial is studying topotecan to see how well it works when given with
or without aflibercept in treating patients with extensive-stage small cell lung cancer.
Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of
tumor cells, either by killing the cells or by stopping them from dividing. Combinations of
biological substances in aflibercept may be able to carry tumor-killing substances directly
to small cell lung cancer cells. Aflibercept may also stop the growth of small cell lung
cancer by blocking blood flow to the tumor. It is not yet known whether topotecan is more
effective with or without aflibercept in treating patients with small cell lung cancer.